Abrard Stanislas, Rineau Emmanuel, Seegers Valerie, Lebrec Nathalie, Sargentini Cyril, Jeanneteau Audrey, Longeau Emmanuelle, Caron Sigrid, Callahan Jean-Christophe, Chudeau Nicolas, Beloncle François, Lasocki Sigismond, Dupoiron Denis
Department of Anesthesiology and Intensive Care, University Hospital of Angers, Angers, France; MITOVASC Institute, INSERM 1083, CNRS 6015, University of Angers, Angers, France; Department of Anesthesiology and Critical Care Medicine, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
Department of Anesthesiology and Intensive Care, University Hospital of Angers, Angers, France; MITOVASC Institute, INSERM 1083, CNRS 6015, University of Angers, Angers, France.
Br J Anaesth. 2023 Jan;130(1):e160-e168. doi: 10.1016/j.bja.2021.11.033. Epub 2022 Jan 5.
Pulmonary complications are an important cause of morbidity and mortality after surgery. We evaluated the clinical effectiveness of noninvasive ventilation (NIV) in preventing postoperative acute respiratory failure.
This is an open, multicentre randomised trial that included patients at high risk of postoperative pulmonary complications after elective or semi-urgent surgery with an Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score ≥45. Patients were randomly assigned to intermittent prophylactic face-mask NIV for 6-8 h day or usual postoperative care. The primary outcome was in-hospital acute respiratory failure within 7 days after surgery. Patients who underwent surgery and postoperative extubation were included in the modified intended-to-treat analysis. Results are presented as n (%) and odds ratios (ORs) with 95% confidence intervals.
Between November 2017 and October 2019, 266 patients were randomised and 253 included in the main analysis. Of these, 203 (80.2%) were male with a mean age of 68 (11) yr and an ARISCAT score of 53 (6); 237 subjects (93.7%) underwent cardiac or thoracic surgery. There were 125 patients allocated to prophylactic NIV and 128 to usual care. Unplanned treatment termination occurred in 58 subjects in the NIV group, which was linked to NIV discomfort for 36 subjects. There was no difference in the incidence of the primary outcome of postoperative acute respiratory failure between treatment groups (NIV: 30 of 125 subjects [24.0%] vs usual care: 35 of 128 subjects [27.3%]; OR 0.97 [0.90-1.04]; P=0.54).
Prophylactic NIV was difficult to implement after high-risk surgery because of low patient compliance. Prophylactic NIV did not prevent acute respiratory failure.
NCT03629431 and EudraCT 2017-001011-36.
肺部并发症是术后发病和死亡的重要原因。我们评估了无创通气(NIV)预防术后急性呼吸衰竭的临床效果。
这是一项开放性、多中心随机试验,纳入了择期或半急诊手术后有术后肺部并发症高风险的患者,其加泰罗尼亚外科患者呼吸风险评估(ARISCAT)评分≥45。患者被随机分配接受每天6 - 8小时的间歇性预防性面罩无创通气或常规术后护理。主要结局是术后7天内的院内急性呼吸衰竭。接受手术和术后拔管的患者纳入改良意向性分析。结果以n(%)和比值比(OR)及95%置信区间表示。
2017年11月至2019年10月期间,266例患者被随机分组,253例纳入主要分析。其中,203例(80.2%)为男性,平均年龄68(11)岁,ARISCAT评分为53(6);237例(93.7%)接受了心脏或胸外科手术。125例患者被分配接受预防性无创通气,128例接受常规护理。无创通气组有58例患者出现计划外治疗终止,其中36例与无创通气不适有关。治疗组之间术后急性呼吸衰竭主要结局的发生率无差异(无创通气组:125例患者中有30例[24.0%],常规护理组:128例患者中有35例[27.3%];OR 0.97[0.90 - 1.04];P = 0.54)。
由于患者依从性低,高危手术后预防性无创通气难以实施。预防性无创通气不能预防急性呼吸衰竭。
NCT03629431和EudraCT 2017 - 001011 - 36。